Abbott (ABT) Q2 2026 earnings review
Exact Sciences Masks Underlying Organic Deceleration
Abbott delivered 13.0% reported revenue growth in Q2, but the headline masks a bifurcated reality. The newly acquired Exact Sciences injected $811 million into the top line, papering over sluggish spots in the legacy portfolio. Medical Devices remained the core organic engine (+8.4% comparable), while Nutrition continues to suffer from a strategic reset (-3.6% comparable) and Diabetes Care unexpectedly decelerated to single-digit growth. Massive acquisition-related charges halved GAAP Net Income (-47.8%), but Adjusted EPS of $1.31 outpaced the prior year. Management raised full-year adjusted EPS guidance to $5.45-$5.60, signaling confidence that H2 will accelerate despite ongoing integration noise.
🐂 Bull Case
The Exact Sciences acquisition immediately established a new growth pillar. Now classified as Cancer Diagnostics, the segment generated $919M in Q2 and grew 13.3% on a comparable basis, driven by Cologuard's mid-teens expansion.
Despite a Q1 respiratory miss and ongoing Nutrition struggles, Abbott raised its FY26 Adjusted EPS guidance midpoint to $5.525. This underscores immense confidence in the Medical Devices pipeline and H2 integration synergies.
🐻 Bear Case
FreeStyle Libre and the broader Diabetes Care segment decelerated to 9.5% and 9.0% comparable growth, respectively. This breaks the multi-year streak of mid-to-high teens growth and raises concerns about U.S. market saturation.
GAAP Net Income collapsed 47.8% YoY as Abbott absorbed $1.362B in specified items, primarily from acquisition charges and intangible amortization. The gap between adjusted and actual profitability is uncomfortably wide.
⚖️ Verdict: ⚪
Neutral to Bullish. The headline growth and guidance raise are impressive, but relying on inorganic injections to mask single-digit Libre growth and declining Nutrition volumes lowers the overall quality of the beat.
Key Themes
Exact Sciences Immediately Transforms Diagnostics
The Exact Sciences deal has aggressively reshaped Abbott's diagnostics profile. With COVID testing headwinds now largely historical noise, Cancer Diagnostics delivered $811 million in inorganic revenue and grew 13.3% on a comparable basis. The growing base of new and repeat Cologuard users provides a highly visible, recurring revenue stream that is shielding weakness in Rapid/Molecular Diagnostics (-8.0% comparable).
Management Prediction Contradicted: Libre Fails to Rebound
In Q1, management confidently predicted a return to double-digit growth for Continuous Glucose Monitors (CGM) in Q2, dismissing saturation concerns as 'myopic.' Q2 data directly contradicts this narrative: Diabetes Care comparable sales grew only 9.0%, and Libre grew 9.5%. Failing to clear the double-digit hurdle despite lapping prior-year comps is a significant red flag for Abbott's historical crown jewel.
Nutrition Turnaround Drags On
The strategic reset in Nutrition—shifting from price-led to volume-led growth—continues to punish the top line. Comparable sales fell 3.6% globally, with U.S. sales plummeting 9.0%. While management highlighted a $127M sequential increase from Q1, the YoY trajectory remains firmly negative, indicating consumer demand has not yet recovered from 2025's aggressive price hikes.
Electrophysiology and Rhythm Management Outperform
Medical Devices remains the organic backbone of the company, and the cardiac portfolio is firing on all cylinders. Electrophysiology surged 13.4% and Rhythm Management grew 9.5% on a comparable basis. This validates the commercial success of the Volt PFA catheter and TactiFlex launches, proving Abbott can take share in high-growth, highly competitive MedTech end markets.
Macro Impact: Foreign Exchange Headwinds
While underlying international demand remains robust, foreign exchange presented an $86 million headwind to total reported sales in Q2. The impact was most pronounced in Medical Devices (-$57M) and Diagnostics (-$22M). Despite this, International Established Pharmaceuticals (EPD) powered through, growing 10.7% comparable in Key Emerging Markets, proving the segment's macro-resilience.
Significant Regulatory Pipeline Milestones
Abbott fortified its product moat with several key Q2 advancements: securing CE Mark for Libre Duo (the first dual glucose-ketone biowearable), completing the TECTONIC U.S. pivotal trial for Coronary Intravascular Lithotripsy (IVL), and submitting the Amulet 360 LAA device to the FDA. These innovations are critical for reinvigorating Diabetes Care and defending Structural Heart share in 2027.
Other KPIs
Accelerating. Calculated adjusted gross margin expanded roughly 110 basis points YoY from 56.9% in 25Q2. This demonstrates excellent underlying profitability and favorable mix shift, likely aided by the high-margin accretion from the Exact Sciences portfolio and strong EPD pricing dynamics.
Reversing. GAAP Net Income was nearly cut in half YoY ($928M vs $1,779M), heavily distorted by specified items. The $1.362B gap consists of $658M in intangible amortization and $704M in other net expenses related to acquisitions, legal reserves, and integration costs. Investors must monitor when these 'one-time' acquisition charges will normalize.
Stable. Abbott returned $2.1 billion to shareholders in the quarter via dividends and share repurchases, confirming that the Exact Sciences acquisition has not derailed the company's aggressive capital return framework.
Guidance
Accelerating. The range was raised from the prior $5.38-$5.58. The new midpoint of $5.525 implies acceleration in the second half of the year, particularly as the Exact Sciences integration matures and the Nutrition segment attempts to find its bottom.
Accelerating. The midpoint of $1.42 represents a solid sequential step up from Q2's $1.31, aligning with management's narrative of building operational momentum into the back half of 2026.
Stable. Management reaffirmed this guidance. H1 comparable sales growth landed at 4.3%. To hit the 7.0% midpoint for the full year, H2 must see a steep acceleration, heavily reliant on a Nutrition volume rebound and the sustained integration of Cologuard.
Key Questions
Libre Growth Trajectory
With Libre comparable growth decelerating to 9.5%—missing your Q1 projection for a return to double-digits—what specific U.S. reimbursement catalysts or product launches (like Libre Duo) are baked into the H2 acceleration assumption?
Nutrition Reset Timeline
U.S. Nutrition comparable sales fell 9.0% in Q2. While there was a sequential dollar improvement, exactly when do you model the YoY volume drag from 2025's strategic pricing actions to fully lap and cross back into positive growth?
Margin Mix and Synergy
Adjusted gross margin expanded nicely this quarter. How much of that expansion was driven organically by the legacy business versus structural accretion from injecting Exact Sciences' high-margin cancer diagnostics into the mix?